-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sutro Biopharma (NASDAQ:STRO) PT Raised to $25.00 at Truist Financial
Sutro Biopharma (NASDAQ:STRO) PT Raised to $25.00 at Truist Financial
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price upped by stock analysts at Truist Financial from $21.00 to $25.00 in a research note issued to investors on Friday, The Fly reports. The firm presently has a "buy" rating on the stock. Truist Financial's price objective indicates a potential upside of 217.66% from the company's current price.
Several other equities analysts have also recently issued reports on the company. Piper Sandler boosted their target price on Sutro Biopharma from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 10th. HC Wainwright decreased their target price on shares of Sutro Biopharma from $30.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, November 9th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $19.67.
Get Sutro Biopharma alerts:Sutro Biopharma Stock Performance
Shares of Sutro Biopharma stock opened at $7.87 on Friday. The firm has a market capitalization of $452.29 million, a P/E ratio of -3.04 and a beta of 0.93. Sutro Biopharma has a 52 week low of $3.33 and a 52 week high of $10.98. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.03. The firm's 50 day moving average is $7.51 and its two-hundred day moving average is $6.52.
Sutro Biopharma (NASDAQ:STRO – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.22). The firm had revenue of $25.15 million during the quarter, compared to analysts' expectations of $11.35 million. Sutro Biopharma had a negative net margin of 175.85% and a negative return on equity of 53.85%. Research analysts forecast that Sutro Biopharma will post -2.59 EPS for the current fiscal year.Institutional Trading of Sutro Biopharma
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Quantbot Technologies LP purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth $37,000. Amalgamated Bank acquired a new stake in Sutro Biopharma in the 1st quarter worth about $44,000. Point72 Hong Kong Ltd purchased a new stake in Sutro Biopharma in the 2nd quarter valued at about $46,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth about $51,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Sutro Biopharma in the third quarter worth approximately $56,000. Hedge funds and other institutional investors own 87.64% of the company's stock.
Sutro Biopharma Company Profile
(Get Rating)
Sutro Biopharma Inc engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Recommended Stories
- Get a free copy of the StockNews.com research report on Sutro Biopharma (STRO)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price upped by stock analysts at Truist Financial from $21.00 to $25.00 in a research note issued to investors on Friday, The Fly reports. The firm presently has a "buy" rating on the stock. Truist Financial's price objective indicates a potential upside of 217.66% from the company's current price.
Sutro Biopharma(纳斯达克股票代码:STRO — 获取评级) The Fly报道,Truist Financial的股票分析师在周五向投资者发布的研究报告中将其目标价格从21.00美元上调至25.00美元。该公司目前对该股的评级为 “买入”。Truist Financial的价格目标表明,该公司的当前价格可能上涨217.66%。
Several other equities analysts have also recently issued reports on the company. Piper Sandler boosted their target price on Sutro Biopharma from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 10th. HC Wainwright decreased their target price on shares of Sutro Biopharma from $30.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, November 9th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $19.67.
其他几位股票分析师最近也发布了有关该公司的报告。派珀·桑德勒在1月10日星期二的一份研究报告中将Sutro Biopharma的目标价格从16.00美元上调至18.00美元,并将该股评为 “增持”。HC Wainwright在11月9日星期三的一份研究报告中将Sutro Biopharma股票的目标价格从30.00美元下调至20.00美元,并对该股设定了 “买入” 评级。五位投资分析师对该股进行了买入评级。根据Marketbeat.com的数据,该公司目前的平均评级为 “买入”,共识目标价为19.67美元。
Sutro Biopharma Stock Performance
Sutro Biopharma股票表现
Shares of Sutro Biopharma stock opened at $7.87 on Friday. The firm has a market capitalization of $452.29 million, a P/E ratio of -3.04 and a beta of 0.93. Sutro Biopharma has a 52 week low of $3.33 and a 52 week high of $10.98. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.03. The firm's 50 day moving average is $7.51 and its two-hundred day moving average is $6.52.
周五,Sutro Biopharma的股票开盘价为7.87美元。该公司的市值为4.5229亿美元,市盈率为-3.04,beta为0.93。Sutro Biopharma创下52周低点3.33美元,52周高点为10.98美元。该公司的速动比率为5.95,流动比率为5.95,债务与权益比率为0.03。该公司的50天移动平均线为7.51美元,其200天移动平均线为6.52美元。
Institutional Trading of Sutro Biopharma
Sutro Biopharma 的机构交易
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Quantbot Technologies LP purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth $37,000. Amalgamated Bank acquired a new stake in Sutro Biopharma in the 1st quarter worth about $44,000. Point72 Hong Kong Ltd purchased a new stake in Sutro Biopharma in the 2nd quarter valued at about $46,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth about $51,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Sutro Biopharma in the third quarter worth approximately $56,000. Hedge funds and other institutional investors own 87.64% of the company's stock.
一些对冲基金和其他机构投资者最近增加了或减少了在STRO的股份。Quantbot Technologies LP在第三季度购买了价值37,000美元的Sutro Biopharma股票的新头寸。合并银行在第一季度收购了Sutro Biopharma的新股份,价值约44,000美元。Point72 Hong Ltd在第二季度收购了Sutro Biopharma的新股份,价值约46,000美元。Allspring Global Investments Holdings LLC在第三季度购买了价值约51,000美元的Sutro Biopharma股票新最后,保诚金融公司在第三季度收购了Sutro Biopharma的新股份,价值约56,000美元。对冲基金和其他机构投资者拥有该公司87.64%的股票。
Sutro Biopharma Company Profile
Sutro Biopharma 公司简介
(Get Rating)
(获取评分)
Sutro Biopharma Inc engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Sutro Biopharma Inc从事药物的发现、开发和制造。它专注于下一代癌症和自身免疫疗法。该公司由 James R. Swartz 和 Sutanto Widjaja 于 2003 年 4 月 21 日创立,总部位于加利福尼亚州南旧金山。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Sutro Biopharma (STRO)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
- 免费获取 StockNews.com 关于 Sutro Biopharma(STRO)的研究报告的副本
- MarketBeat:本周回顾 01/09-01/13
- 随着银行为衰退做准备,摩根大通下跌
- 为什么 Bed Bath & Beyond 的股价上涨了 261%?
- Roku 股价正在走势,原因如下
- Carvana 股票上涨,这是你需要知道的
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Sutro Biopharma Daily 的新闻和评 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Sutro Biopharma及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧